Siddhartha Mukherjee, MD

Academic Appointments

  • Assistant Professor of Medicine
Siddhartha Mukherjee, MD

Hematologist and oncologist Siddhartha Mukherjee was born in New Delhi, India. He holds a BS in biology from Stanford University, a DPhil in immunology from Oxford University (where he was a Rhodes Scholar), and an MD from Harvard Medical School. He completed his internal medicine residency and an oncology fellowship at Massachusetts General Hospital. Dr. Murkherjee is an assistant professor of medicine at Columbia University Medical Center. He lives in Manhattan with his wife, artist Sarah Sze, and their two daughters.

His Pulitzer Prize-winning book, The Emperor of All Maladies: A Biography of Cancer, tells the story of cancer from its first description in an ancient Egyptian scroll to the gleaming laboratories of modern research institutions. A three-part documentary series based on the book, directed by Barak Goodman and executive produced by Ken Burns, debuts on PBS stations March 30 and continues on March 31 and April 1. The film interweaves a sweeping historical narrative with intimate stories about contemporary patients and an investigation into the latest scientific breakthroughs.

Dr. Mukherjee’s research lab studies the biology of blood development, in particular, malignant and pre-malignant diseases such as myelodysplasia (MDS) and acute myelogenous leukemia (AML). The eventual goal is to develop novel drugs against these diseases.

Departments and Divisions

  • Department of Medicine
    Division of Hematology/Oncology

Board Certifications

  • Medical Oncology

Areas of Expertise

  • Lymphoma
  • Myelodysplastic Syndrome
  • Myeloma

Education and Training

  • Residency: 2003 Massachusetts General Hospital
  • Fellowship: 2006 Dana Farber Cancer Institute - Harvard Medical School

Centers / Institutes / Programs

  • Herbert Irving Comprehensive Cancer Center
  • Columbia Stem Cell Initiative

Provider Affiliations

  • NewYork-Presbyterian / Columbia University Irving Medical Center

Insurance Programs

Please contact the provider's office directly to verify that your particular insurance is accepted.

  • AETNA [Aetna Signature Administrators, EPO, HMO, Medicare Managed Care, NYP Employee Plan, NY Signature, POS, PPO, Student Health]
  • Affinity Health Plan [Essential Plan, Medicaid Managed Care]
  • AgeWell [Medicare Managed Care, Special Needs]
  • Amida Care [Special Needs]
  • CIGNA [EPO, Great West (National), HMO, POS, PPO]
  • Emblem/GHI [Medicare Managed Care, PPO]
  • Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
  • Empire Blue Cross/Blue Shield [EPO, HMO, Medicare Managed Care, PPO]
  • Empire Blue Cross Blue Shield HealthPlus [Child/Family Health Plus, Essential Plan, Medicaid Managed Care]
  • Fidelis Care [Child/Family Health Plus, Essential Plan, Medicaid Managed Care, Medicare Managed Care]
  • Healthfirst [Child/Family Health Plus, Leaf (Exchange), Medicaid Managed Care, Medicare Managed Care]
  • Local 1199 [Local 1199]
  • MagnaCare (National) [MagnaCare]
  • Medicare [Railroad, Traditional Medicare]
  • Multiplan [Multiplan]
  • MVP Health Care [Child/Family Health Plus, Essential Plan, HMO, Medicaid Managed Care]
  • Oxford Health Plans [Freedom, Liberty]
  • RiverSpring [Special Needs]
  • UnitedHealthcare [Compass (Exchange), Empire Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
  • VNSNY CHOICE [Medicare Managed Care, SelectHealth, Special Needs]
  • WellCare [Medicaid Managed Care, Medicare Managed Care]

This provider does not accept new patients

NIH Grants

  • TARGETING SPLICING FACTOR MUTATIONS IN MYELDYSPLASTIC SYNDROMES IN CANCER (Private)

    Jun 1 2018 - May 31 2021

    COMBINING IMMUNOTOXIN-BASED CONDITIONING AND ADC WITH ALLOGENEIC HSCT: A TWO-HIT ON LEUKEMIA APPROACH (Private)

    Jan 1 2020 - Dec 31 2020

    OSTEOCHONDRORETICULAR (OCR) CELLS AS SOURCES OF CARTILAGE REPAIR IN OSTEOARTHRITIS (Federal Gov)

    Jul 1 2016 - Jun 30 2020

    ENGINEERINGCAR-TARGETED, CD94/NKG2A NULL NK CELLS FOR SAFER AND MORE EFFICIENT EFFECTOR IMMUNE CELLS (Private)

    Jul 1 2019 - Jan 31 2020

    A PHASE 1 TRIAL OF PERSONALIZED/PRECISION THERAPEUTICS FOR MYELODYSPLASTIC SYNDROME (MDS) USING BONE MARROW ORGANOID (BM-O) SCREENING (Private)

    Apr 1 2016 - Mar 31 2019

    PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITION TO TREAT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) (Private)

    Feb 26 2016 - Feb 25 2019

    YES 1 AND CTNND1 AS QUIESCENCE REGULATORS IN HEMATOPOIETIC STEM CELLS (Federal Gov)

    Aug 1 2013 - Apr 30 2018

    YES 1 AND CTNND1 AS QUIESCENCE REGULATORS IN HEMATOPOIETIC STEM CELLS (Federal Gov)

    Aug 1 2013 - Apr 30 2018

    YES 1 AND CTNND1 AS QUIESCENCE REGULATORS IN HEMATOPOIETIC STEM CELLS (Federal Gov)

    Aug 1 2013 - Apr 30 2018

    YES 1 AND CTNND1 AS QUIESCENCE REGULATORS IN HEMATOPOIETIC STEM CELLS (Federal Gov)

    Aug 1 2013 - Apr 30 2018

    CHIMERIC ANTIGEN T CELL THERAPIES IN ACUTE MYELOID LEUKEMIA (Private)

    Apr 29 2016 - Apr 28 2018

    CLINICAL ANNOTATION AND PERSONALIZED TREATMENT FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES (Private)

    Nov 1 2014 - Oct 31 2016

    CENTER FOR HIGH-THROUGHPUT MINIMALLY-INVASIVE RADIATION BIODOSIMETRY (Federal Gov)

    Aug 31 2005 - Jul 31 2016

    CENTER FOR HIGH-THROUGHPUT MINIMALLY-INVASIVE RADIATION BIODOSIMETRY (Federal Gov)

    Aug 31 2005 - Jul 31 2016

    THE ROLE OF XLF IN HEMATOPOIETIC STEM CELL MAINTENANCE AND FUNCTION (Federal Gov)

    Aug 15 2013 - Jul 31 2015

    THE ROLE OF XLF IN HEMATOPOIETIC STEM CELL MAINTENANCE AND FUNCTION (Federal Gov)

    Aug 15 2013 - Jul 31 2015

    THE ROLE OF XLF IN HEMATOPOIETIC STEM CELL MAINTENANCE AND FUNCTION (Federal Gov)

    Aug 15 2013 - Jul 31 2015

    ILLUMINATE THE PATHOPHYSIOLOGY OF MDS WITH SRSF2 (Private)

    Jul 1 2014 - Jun 30 2015

    COLLABORATIVE EFFORT IN STEM CELL BIOLOGY (Private)

    Jul 1 2010 - Jun 30 2014

    EXOME AND NEXT GENERATION SEQUENCING TO IDENTIFY RARS-SPECIFIC TARGETABLE DEFECTS (Private)

    Jul 1 2012 - Jun 30 2014

    CANCER STEM CELL SPECIFIC LETHALITY IN ACUTE MYELOID LEUKEMIA STEM CELLS BY MODULATION OF PES-1 AND DFFB (Private)

    Jan 1 2012 - Dec 31 2013

    DISSECTINGTHE ROLES OF YES-1, MIIT3 AND CTNND1 IN LEUKEMIA STEM CELL QUIESCENCE (Private)

    Jan 1 2011 - Dec 31 2013

    IDENTIFICATION OF FUNCTIONAL TUMOR-STROMAL INTERACTIONS IN T HE BONE MARROW (Federal Gov)

    Sep 30 2009 - Aug 31 2012

    THE REGULATION OF LEUKEMIA-ENGRAFTING CELLS BY THE HEMATOPOE ITIC STEM CELL NICHE (Federal Gov)

    Sep 30 2006 - Jul 31 2011